{
    "xml": "<topic id=\"PHP5698\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/canakinumab\" basename=\"canakinumab\" title=\"CANAKINUMAB\">\n<title>CANAKINUMAB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1336\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/canakinumab\">Canakinumab</xref>\n</p>\n<data name=\"vtmid\">16591711000001109</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_805434570\" title=\"Monoclonal antibodies\">Monoclonal antibodies</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n<data name=\"secondaryDomainsOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP42560\" outputclass=\"drugAction\" rev=\"1.8\" parent=\"/drugs/canakinumab\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Canakinumab is a recombinant human monoclonal antibody that selectively inhibits interleukin-1 beta receptor binding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42543\" outputclass=\"indicationsAndDose\" rev=\"1.23\" parent=\"/drugs/canakinumab\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Acute gout in patients whose condition has not responded adequately to treatment with NSAIDs or colchicine, or who are intolerant of them</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8239;mg for 1 dose, dose may be repeated at least 12 weeks after initial response if symptoms recur, patients who do not respond to initial dose should not be retreated.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of cryopyrin-associated periodic syndromes, including severe forms of familial cold auto-inflammatory syndrome (or familial cold urticaria), Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease (also known as chronic infantile neurological cutaneous and articular syndrome)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42568\" outputclass=\"contraindications\" rev=\"1.9\" parent=\"/drugs/canakinumab\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Active infection</ph>; <ph outputclass=\"contraindication\">leucopenia</ph>; <ph outputclass=\"contraindication\">neutropenia</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42582\" outputclass=\"cautions\" rev=\"1.14\" parent=\"/drugs/canakinumab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">History of recurrent infection</ph>; <ph outputclass=\"caution\">latent and active tuberculosis</ph>; <ph outputclass=\"caution\">predisposition to infection</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Vaccinations</p>\n<p>Patients should receive all recommended vaccinations (including pneumococcal and inactivated influenza vaccine) before starting treatment; avoid live vaccines unless potential benefit outweighs risk&#8212;consult product literature for further information.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42541\" outputclass=\"interactions\" rev=\"1.17\" parent=\"/drugs/canakinumab\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (canakinumab).</p>\n<p>Contra-indicated with concomitant use with tumour necrosis factor inhibitors (possible increased risk of infections).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42536\" outputclass=\"sideEffects\" rev=\"1.16\" parent=\"/drugs/canakinumab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Back pain</ph>; <ph outputclass=\"sideEffect\">increased susceptibility to infection (including serious infection)</ph>; <ph outputclass=\"sideEffect\">injection-site reactions</ph>; <ph outputclass=\"sideEffect\">malaise</ph>; <ph outputclass=\"sideEffect\">neutropenia</ph>; <ph outputclass=\"sideEffect\">vertigo</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Gastro-oesophageal reflux</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Malignancy</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42576\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/canakinumab\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Effective contraception required during treatment and for up to 3 months after last dose.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42540\" outputclass=\"pregnancy\" parent=\"/drugs/canakinumab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid unless potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42591\" outputclass=\"breastFeeding\" parent=\"/drugs/canakinumab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Consider if benefit outweighs risk&#8212;not known if present in human milk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42546\" outputclass=\"hepaticImpairment\" parent=\"/drugs/canakinumab\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>No information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42538\" outputclass=\"renalImpairment\" parent=\"/drugs/canakinumab\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Limited information available but manufacturer advises no dose adjustment required.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42537\" outputclass=\"preTreatmentScreening\" rev=\"1.8\" parent=\"/drugs/canakinumab\">\n<title>Pre-treatment screening</title>\n<body>\n<section>\n<sectiondiv>\n<p>Patients should be evaluated for latent and active tuberculosis before starting treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42524\" outputclass=\"monitoringRequirements\" parent=\"/drugs/canakinumab\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor full blood count including neutrophil count before starting treatment, 1&#8211;2 months after starting treatment, and periodically thereafter.</p>\n<p>Monitor for signs and symptoms of tuberculosis during and after treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP5698-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/canakinumab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75201\" title=\"Powder for solution for injection\" namespace=\"/drugs/canakinumab/powder-for-solution-for-injection\">Powder for solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78607\" namespace=\"/treatment-summaries/gout\" title=\"Gout\" count=\"1\" rel=\"backlink\">Gout</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1336\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/canakinumab\" title=\"Canakinumab\" count=\"1\" rel=\"link\">Canakinumab</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75201\" namespace=\"/drugs/canakinumab/powder-for-solution-for-injection\" title=\"Powder for solution for injection\" count=\"1\" rel=\"link\">Powder for solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP5698",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/canakinumab",
    "basename": "canakinumab",
    "title": "CANAKINUMAB",
    "interactants": [
        {
            "id": "bnf_int_1336",
            "label": "Canakinumab"
        }
    ],
    "vtmid": "16591711000001109",
    "drugClassification": [
        "Monoclonal antibodies"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "secondaryDomainsOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Canakinumab is a recombinant human monoclonal antibody that selectively inhibits interleukin-1 beta receptor binding.",
                "html": "<p>Canakinumab is a recombinant human monoclonal antibody that selectively inhibits interleukin-1 beta receptor binding.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Acute gout in patients whose condition has not responded adequately to treatment with NSAIDs or colchicine, or who are intolerant of them",
                        "html": "Acute gout in patients whose condition has not responded adequately to treatment with NSAIDs or colchicine, or who are intolerant of them"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "150 mg for 1 dose, dose may be repeated at least 12 weeks after initial response if symptoms recur, patients who do not respond to initial dose should not be retreated.",
                        "html": "<p>150&#8239;mg for 1 dose, dose may be repeated at least 12 weeks after initial response if symptoms recur, patients who do not respond to initial dose should not be retreated.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of cryopyrin-associated periodic syndromes, including severe forms of familial cold auto-inflammatory syndrome (or familial cold urticaria), Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease (also known as chronic infantile neurological cutaneous and articular syndrome)",
                        "html": "Treatment of cryopyrin-associated periodic syndromes, including severe forms of familial cold auto-inflammatory syndrome (or familial cold urticaria), Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease (also known as chronic infantile neurological cutaneous and articular syndrome)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature).",
                        "html": "<p>(consult product literature).</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Active infection",
                "html": "Active infection"
            },
            {
                "type": "contraindications",
                "textContent": "leucopenia",
                "html": "leucopenia"
            },
            {
                "type": "contraindications",
                "textContent": "neutropenia",
                "html": "neutropenia"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "History of recurrent infection",
                "html": "History of recurrent infection"
            },
            {
                "type": "cautions",
                "textContent": "latent and active tuberculosis",
                "html": "latent and active tuberculosis"
            },
            {
                "type": "cautions",
                "textContent": "predisposition to infection",
                "html": "predisposition to infection"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Vaccinations",
                "textContent": "Patients should receive all recommended vaccinations (including pneumococcal and inactivated influenza vaccine) before starting treatment; avoid live vaccines unless potential benefit outweighs risk&#8212;consult product literature for further information.",
                "html": "<p>Patients should receive all recommended vaccinations (including pneumococcal and inactivated influenza vaccine) before starting treatment; avoid live vaccines unless potential benefit outweighs risk&#8212;consult product literature for further information.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (canakinumab).\n\nContra-indicated with concomitant use with tumour necrosis factor inhibitors (possible increased risk of infections).",
                "html": "<p>Appendix 1 (canakinumab).</p><p>Contra-indicated with concomitant use with tumour necrosis factor inhibitors (possible increased risk of infections).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Back pain",
                        "html": "Back pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "increased susceptibility to infection (including serious infection)",
                        "html": "increased susceptibility to infection (including serious infection)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "injection-site reactions",
                        "html": "injection-site reactions",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "malaise",
                        "html": "malaise",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "neutropenia",
                        "html": "neutropenia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vertigo",
                        "html": "vertigo",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Gastro-oesophageal reflux",
                        "html": "Gastro-oesophageal reflux",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Malignancy",
                        "html": "Malignancy",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Effective contraception required during treatment and for up to 3 months after last dose.",
                "html": "<p>Effective contraception required during treatment and for up to 3 months after last dose.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid unless potential benefit outweighs risk.",
                "html": "<p>Manufacturer advises avoid unless potential benefit outweighs risk.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Consider if benefit outweighs risk&#8212;not known if present in human milk.",
                "html": "<p>Consider if benefit outweighs risk&#8212;not known if present in human milk.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "No information available.",
                "html": "<p>No information available.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Limited information available but manufacturer advises no dose adjustment required.",
                "html": "<p>Limited information available but manufacturer advises no dose adjustment required.</p>"
            }
        ]
    },
    "preTreatmentScreening": {
        "preTreatmentScreening": [
            {
                "type": "preTreatmentScreening",
                "textContent": "Patients should be evaluated for latent and active tuberculosis before starting treatment.",
                "html": "<p>Patients should be evaluated for latent and active tuberculosis before starting treatment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor full blood count including neutrophil count before starting treatment, 1&#8211;2 months after starting treatment, and periodically thereafter.\n\nMonitor for signs and symptoms of tuberculosis during and after treatment.",
                "html": "<p>Monitor full blood count including neutrophil count before starting treatment, 1&#8211;2 months after starting treatment, and periodically thereafter.</p><p>Monitor for signs and symptoms of tuberculosis during and after treatment.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75201",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78607",
                "label": "Gout",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1336",
                "label": "Canakinumab",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75201",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}